Biosimilar to Remicade
Recent approval under new international Project Orbis.
Hemoglobin S Polymerization inhibitor oral treatment.
Approved for patients 18 years of age and older
Antibiotic with a novel penetrative mechanism.
Expected U.S. launch in 2023.
First and currently only biological targeting P-selectin.
MCL is an aggressive form of NHL
Shown to reduce regular RBC transfusions in adults with beta thalassemia.
First and currently only rifabutin-based H. pylori therapy approved.